Biotech | April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Bayer will be setting up 27 telemedicine centres in 12 districts across 8 states with implementing partners Telerad RxDx and Piramal Swasthya
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
A major unresolved question in the field, however, is how do this machinery rapidly searches for and finds rare stretches of damage amid the "vast fields" of undamaged DNA
Subscribe To Our Newsletter & Stay Updated
